Showing 1199 results
- Media Release /Divestment includes Xiidra®, on-market treatment for dry eye disease and additional ophthalmic investigational therapiesNovartis advances strategy of focused portfolio and prioritized therapeutic…
- Media Release /Biosimilar Tyruko® approved for all indications of reference medicine, as first and only biosimilar to treat relapsing forms of multiple sclerosis (MS) in EuropeDecision based on evidence from…
- Media Release /Phase III NETTER-2 trial met primary endpoint of improvement in progression-free survival (PFS) and key secondary endpoint of objective response rate (ORR) in patients with Grade 2 and 3 advanced…
- Media Release /Sandoz shares (SDZ) to be listed and traded on SIX Swiss Exchange; ADRs to be traded on OTCQX®, first trading day October 4, 2023Sandoz to be included in key Swiss market indicesInvestment grade…
- Media Release /Positive CHMP opinion based on comprehensive package of analytical, pre-clinical and clinical dataBreast and gastric cancers are among most common types of cancer, accounting together for nearly half…
- Media Release /Shareholders approve the proposed 100% Spin-off of Sandoz, the Generics and Biosimilars business of NovartisShareholders also approve a reduction of share capital in connection with the Spin-off…
- Media Release /Les actionnaires approuvent le projet de scission à 100% de Sandoz, l’activité Génériques et Biosimilaires de NovartisLes actionnaires approuvent également une réduction du capital social dans le…
- Media Release /Die Aktionärinnen und Aktionäre stimmen dem geplanten 100%igen Spin-off von Sandoz, dem Generika- und Biosimilars-Geschäft von Novartis, zu.Die Aktionärinnen und Aktionäre stimmen ausserdem einer…
- Media Release /Patient-reported outcomes (PROs) from the Phase III NATALEE trial show that patients receiving adjuvant Kisqali plus endocrine therapy (ET) for up to three years maintained physical and social…
- Media Release /Agreement with Samsung Bioepis gives Sandoz exclusive commercialization rights to biosimilar SB17 ustekinumab in Europe and North AmericaUstekinumab is a fully human monoclonal antibody to…
Pagination
- ‹ Previous page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- …
- 120
- › Next page